Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

TAS6417, a novel epidermal growth factor receptor inhibitor targeting exon 20 insertion mutations.

Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K.

Mol Cancer Ther. 2018 May 10. pii: molcanther.1206.2017. doi: 10.1158/1535-7163.MCT-17-1206. [Epub ahead of print]

PMID:
29748209
2.

Muscle RAS oncogene homolog (MRAS) recurrent mutation in Borrmann type IV gastric cancer.

Yasumoto M, Sakamoto E, Ogasawara S, Isobe T, Kizaki J, Sumi A, Kusano H, Akiba J, Torimura T, Akagi Y, Itadani H, Kobayashi T, Hasako S, Kumazaki M, Mizuarai S, Oie S, Yano H.

Cancer Med. 2017 Jan;6(1):235-244. doi: 10.1002/cam4.959. Epub 2016 Nov 28.

3.

Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo.

Hirai H, Shimomura T, Kobayashi M, Eguchi T, Taniguchi E, Fukasawa K, Machida T, Oki H, Arai T, Ichikawa K, Hasako S, Haze K, Kodera T, Kawanishi N, Takahashi-Suziki I, Nakatsuru Y, Kotani H, Iwasawa Y.

Cell Cycle. 2010 Apr 15;9(8):1590-600. Epub 2010 Apr 15.

PMID:
20372067
4.

Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo.

Hirai H, Takahashi-Suziki I, Shimomura T, Fukasawa K, Machida T, Takaki T, Kobayashi M, Eguchi T, Oki H, Arai T, Ichikawa K, Hasako S, Kodera T, Kawanishi N, Nakatsuru Y, Kotani H, Iwasawa Y.

Invest New Drugs. 2011 Aug;29(4):534-43. doi: 10.1007/s10637-009-9384-8. Epub 2010 Jan 19.

PMID:
20084424
5.

MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.

Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, Miki S, Kawanishi N, Ohkubo M, Kotani H, Iwasawa Y.

Mol Cancer Ther. 2010 Jan;9(1):157-66. doi: 10.1158/1535-7163.MCT-09-0609. Epub 2010 Jan 6.

Supplemental Content

Loading ...
Support Center